Effects of Pau d' Arco in Primary Dysmenorrhea

NCT ID: NCT04245540 Phase: EARLY_PHASE1 Status: COMPLETED Enrollment: 12 Completion: 2022-12-15

Conditions

Primary Dysmenorrhea

Interventions

Pau d' Arco

Summary

A single arm, open-label trial evaluating safety and tolerability of encapsulated Tabebuia avellanedae in 12 generally healthy women aged 18-45 with primary dysmenorrhea (PDM). This will be the first study evaluating the safety and tolerability of Tabebuia avellanedae in PDM. We also aim to collect proof-of-concept mechanistic data supporting the hypothesis that Tabebuia avellanedae reduces PGE2 concentration in vivo in women with PDM.

Primary Outcome

Red Blood Cell Count

Source

ClinicalTrials.gov